What's New - Drug Products

Files added to the Web site are also posted here in the What's New section for three weeks. Once you have browsed through the entire site, all you need to do to keep current is make sure you visit this page more than once every three weeks.

Weekly Drug NOC updates

2018

September

Updated Register of Certificates of Supplementary Protection and Applications [2018-09-18]
Register of Innovative Drugs [2018-09-18]
Notice of Compliance (NOC) Data Extracts [2018-09-14]
Updated List of Drugs for an Urgent Public Health Need [2018-09-11]
Post-Authorization Activity Table (PAAT) for Tivicay [2018-09-11]
Post-Authorization Activity Table (PAAT) for Eloctate [2018-09-11]
Post-Authorization Activity Table (PAAT) for Durezol [2018-09-11]
Post-Authorization Activity Table (PAAT) for Bavencio [2018-09-11]
Post-Authorization Activity Table (PAAT) for Spinraza [2018-09-11]
Regulatory Decision Summary for Panhematin [2018-09-11]
Regulatory Decision Summary for Aimovig [2018-09-11]
Regulatory Decision Summary for Repatha [2018-09-11]
Regulatory Decision Summary for Harvoni [2018-09-11]
Regulatory Decision Summary for Bexsero [2018-09-11]
Regulatory Decision Summary for Nuceiva [2018-09-11]
Regulatory Decision Summary for Soliris [2018-09-11]
Regulatory Decision Summary for Monoferric [2018-09-07]
Regulatory Decision Summary for HADLIMA, HADLIMA PushTouch [2018-09-07]
Regulatory Decision Summary for Ibrance [2018-09-07]
Regulatory Decision Summary for Penthrox [2018-09-07]
Regulatory Decision Summary for Gazyva [2018-09-07]
Regulatory Decision Summary for Erleada [2018-09-07]
Regulatory Decision Summary for Hemlibra [2018-09-07]
Summary of Cancellation: Human heterologous liver cells, HHLivC (HepaBridge) (Control number 205160) [2018-09-07]
Post-Authorization Activity Table (PAAT) for Forxiga [2018-09-07]
Post-Authorization Activity Table (PAAT) for Mekinist [2018-09-07]

August

DPD Extracts [2018-09-04]
Notice: Publication of Update to the Guidance Document: Certificate of Supplementary Protection Regulations [2018-09-04]
Notice of Compliance (NOC) Data Extracts [2018-08-31]
Register of Innovative Drugs [2018-08-31]
Submissions Under Review [2018-08-30]
Updated Register of Certificates of Supplementary Protection and Applications [2018-08-29]
Summary Basis of Decision (SBD) for Erleada [2018-08-27]
Updated - Notice regarding the Post-Notice of Compliance (NOC) Changes – Notices of Change: Level III Form [2018-08-27]
Notice of Compliance (NOC) Data Extracts [2018-08-24]
TPD Quarterly Drug Submission Performance report for April - June 2018 [2018-08-24]
Notice: Prescription Drug List (PDL): Nicotine Qualifier Clarification [2018-08-23]
Regulatory Decision Summary for Opdivo [2018-08-22]
Regulatory Decision Summary for Arbesda Respiclick [2018-08-22]
Regulatory Decision Summary for Hizentra [2018-08-22]
Regulatory Decision Summary for Zykadia [2018-08-22]
Regulatory Decision Summary for Trelegy Ellipta [2018-08-22]
Regulatory Decision Summary for Monoferric [2018-08-22]
Post-Authorization Activity Table (PAAT) for Imbruvica [2018-08-22]
Post-Authorization Activity Table (PAAT) for Lenvima [2018-08-22]
Post-Authorization Activity Table (PAAT) for Remsima [2018-08-22]
Post-Authorization Activity Table (PAAT) for Praxbind [2018-08-22]
Summary Basis of Decision (SBD) for Besponsa [2018-08-22]
Summary Basis of Decision (SBD) for HADLIMA / HADLIMA PUSHTOUCH [2018-08-20]
Notice: Phase III of Pre-Market Transparency Initiatives for Prescription Drugs [2018-08-03]
Notice of Compliance (NOC) Data Extracts [2018-08-17]
Notice: Prescription Drug List (PDL): Multiple Additions [2018-08-16]
Updated Register of Certificates of Supplementary Protection and Applications [2018-08-16]
Register of Innovative Drugs [2018-08-16]
Product Monograph Brand Safety Updates – July 2018 [2018-08-14]
Post-Authorization Activity Table (PAAT) for Mictoryl/Mictoryl Pediatric [2018-08-13]
Post-Authorization Activity Table (PAAT) for Sovaldi [2018-08-13]
Post-Authorization Activity Table (PAAT) for Alprolix [2018-08-13]
Post-Authorization Activity Table (PAAT) for Istodax [2018-08-13]
Summary of Cancellation for AVASTIN (Control number 207217) [2018-08-13]
Regulatory Decision Summary for Avastin [2018-08-13]
Regulatory Decision Summary for Tafinlar [2018-08-13]
Regulatory Decision Summary for Steglujan [2018-08-13]
Regulatory Decision Summary for Probuphine [2018-08-13]
Summary Basis of Decision (SBD) for Probuphine [2018-08-13]
Regulatory Decision Summary for Foquest [2018-08-13]
Regulatory Decision Summary for Ikervis [2018-08-13]
Updated Register of Certificates of Supplementary Protection and Applications [2018-08-10]
Notice of Compliance (NOC) Data Extracts [2018-08-10]
Updated List of Drugs for an Urgent Public Health Need [2018-08-10]
Consultation: Release of Draft (Step 2) ICH M9 Guidance: Biopharmaceutics Classification System-based Biowavers [2018-08-08]
Qualifying Notice – Alunbrig [2018-08-03]
Updated Register of Certificates of Supplementary Protection and Applications [2018-08-03]
DPD Extracts [2018-08-01]

July

Register of Innovative Drugs [2018-07-30]
Notice of Compliance (NOC) Data Extracts [2018-07-27]
Updated Register of Certificates of Supplementary Protection and Applications [2018-07-25]
Notice: Prescription Drug List (PDL): Multiple additions [2018-07-25]
Submissions Under Review [2018-07-23]
Updated List of Drugs for an Urgent Public Health Need [2018-07-23]
Notice of Compliance (NOC) Data Extracts [2018-07-20]
Register of Innovative Drugs [2018-07-20]
Regulatory Decision Summary for Imbruvica [2018-07-17]
Post-Authorization Activity Table (PAAT) for Viibryd [2018-07-17]
Post-Authorization Activity Table (PAAT) for Lixiana [2018-07-17]
Post-Authorization Activity Table (PAAT) for Lonsurf [2018-07-17]
Post-Authorization Activity Table (PAAT) for Epclusa [2018-07-17]
Post-Authorization Activity Table (PAAT) for Sunvepra [2018-07-17]
Post-Authorization Activity Table (PAAT) for Akynzeo [2018-07-17]
Post-Authorization Activity Table (PAAT) for Daklinza [2018-07-17]
Regulatory Decision Summary for Segluromet [2018-07-17]
Post-Authorization Activity Table (PAAT) for Eloctate [2018-07-17]
Post-Authorization Activity Table (PAAT) for DaTscan [2018-07-17]
Product Monograph Brand Safety Updates [2018-07-16]
Notice: Australia Canada Singapore Switzerland (ACSS) Consortium – Approval of Erleada [2018-07-13]
Notice of Compliance (NOC) Data Extracts [2018-07-13]
Notifying Health Canada of Foreign Actions - Guidance Document for Industry - Summary [2018-07-12]
Notice of Intent to Amend: Prescription Drug List (PDL): Phytocannabinoids [2018-07-11]
Therapeutic Products Directorate Statistical Report 2017/2018 [2018-07-11]
Notice: Health Canada and United States Food and Drug Administration Joint Public Consultation on International Council on Harmonisation Guidelines for Registration of Pharmaceuticals for Human Use [2018-07-10]
Notice of Compliance (NOC) Data Extracts [2018-07-06]
Summary of Cancellation: lorcaserin hydrochloride (*Belviq) [2018-07-06]
Post-Authorization Activity Table (PAAT) for Galafold [2018-07-06]
Post-Authorization Activity Table (PAAT) for Fasenra [2018-07-06]
Post-Authorization Activity Table (PAAT) for Xiidra [2018-07-06]
Post-Authorization Activity Table (PAAT) for Shingrix [2018-07-06]
Post-Authorization Activity Table (PAAT) for Zontivity [2018-07-06]
Post-Authorization Activity Table (PAAT) for Lonsurf [2018-07-06]
Qualifying Notice – Opdivo [2018-07-05]
Regulatory Decision Summary for Latuda [2018-07-05]
Post-Authorization Activity Table (PAAT) for Tremfya [2018-07-05]
Post-Authorization Activity Table (PAAT) for Renflexis [2018-07-05]
Post-Authorization Activity Table (PAAT) for Rupall (Formerly Rupatadine) [2018-07-05]
Post-Authorization Activity Table (PAAT) for Fetzima [2018-07-05]
Notice: Prescription Drug List (PDL): Multiple Additions [2018-07-04]

June

DPD Extracts [2018-07-03]
Register of Innovative Drugs [2018-06-29]
Notice of Compliance (NOC) Data Extracts [2018-06-29]
Updated Register of Certificates of Supplementary Protection and Applications [2018-06-28]
Summary Basis of Decision (SBD) for SILIQ [2018-06-29]
Post-Authorization Activity Table (PAAT) for Brinavess [2018-06-29]
Post-Authorization Activity Table (PAAT) for Dupixent [2018-06-29]
Post-Authorization Activity Table (PAAT) for Kanuma [2018-06-29]
Post-Authorization Activity Table (PAAT) for Ozanex [2018-06-29]
Post-Authorization Activity Table (PAAT) for Ozempic [2018-06-29]
Post-Authorization Activity Table (PAAT) for Rebinyn [2018-06-29]
Post-Authorization Activity Table (PAAT) for Erelzi [2018-06-29]
Regulatory Decision Summary for Dysport Aesthetic [2018-06-29]
Regulatory Decision Summary for Mvasi [2018-06-29]
Regulatory Decision Summary for Siliq [2018-06-29]
Regulatory Decision Summary for Imfinzi [2018-06-29]
Regulatory Decision Summary for Xgeva [2018-06-29]
Regulatory Decision Summary for Alphanate [2018-06-29]
Post-Authorization Activity Table (PAAT) for Maviret [2018-06-29]
Post-Authorization Activity Table (PAAT) for Procysbi [2018-06-29]
Post-Authorization Activity Table (PAAT) for Eperzan [2018-06-29]
Post-Authorization Activity Table (PAAT) for Prevymis [2018-06-29]
Post-Authorization Activity Table (PAAT) for Nesina [2018-06-29]
Post-Authorization Activity Table (PAAT) for Forxiga [2018-06-29]
Post-Authorization Activity Table (PAAT) for Aubagio [2018-06-29]
Post-Authorization Activity Table (PAAT) for Saflutan [2018-06-29]
Submissions Under Review [2018-06-28]
Notice - Release of the revised Notice regarding the Post-Notice of Compliance (NOC) Changes – Notices of Change: Level III Form [2018-06-26]
Notice: Release of the revised Guidance Document: Post-Notice of Compliance (NOC) Changes - Safety and Efficacy [2018-06-26]
Notice: Release of the revised Post-Notice of Compliance (NOC) Changes - Framework Guidance Document [2018-06-26]
Notice: Release of Draft (Step 2) ICH Guidance: Q3D(R1): Revision of Cadmium Inhalation PDE [2018-06-26]
Radiopharmaceuticals, Kits, and Generators - Submission Information for Schedule C Drugs: Draft Guidance Document for Consultation [2018-06-26]
Notice: Step 4 - ICH S9 Guideline: Nonclinical Evaluation for Anticancer Pharmaceuticals, Questions and Answers [2018-06-26]
Notice to industry: Aligned reviews between Health Canada and health technology assessment organizations [2018-06-22]
Register of Innovative Drugs [2018-06-22]
Updated Register of Certificates of Supplementary Protection and Applications [2018-06-22]
Notice of Compliance (NOC) Data Extracts - June 22, 2018 [2018-06-22]
Updated List of Drugs for an Urgent Public Health Need [2018-06-21]
TPD/BGTD/NNHPD Quarterly Drug Submission Performance report for Q4-2017-2018 and TPD/BGTD/NNHPD Annual Drug Submission Performance report for 2017-2018 [2018-06-15]
Register of Innovative Drugs [2018-06-15]
Notice of Compliance (NOC) Data Extracts - June 15, 2018 [2018-06-15]
Updated List of Drugs for an Urgent Public Health Need [2018-06-14]
Product Monograph Brand Safety Updates - May 2018 [2018-06-13]
Register of Innovative Drugs [2018-06-13]
Guidance Document - Fees for the Right to Sell Drugs [2018-06-12]
Summary - Guidance Document: Cancellation of a Drug Identification Number (DIN) and Notification of Discontinuation of Sales [2018-06-12]
Qualifying Notice - Imfinzi [2018-06-08]
Notice of Compliance (NOC) Data Extracts - June 8, 2018 [2018-06-08]
Updated Register of Certificates of Supplementary Protection and Applications [2018-06-07]
Notice: Health Canada Review of Vitamin D Levels for Non-Prescription Use [2018-06-04]
DPD Extracts [2018-06-01]
Qualifying Notice - Bavencio [2018-05-31]
Notice of Compliance (NOC) Data Extracts - June 1, 2018 [2018-06-01]
Post-Authorization Activity Table (PAAT) for Ocrevus [2018-06-01]
Post-Authorization Activity Table (PAAT) for Defitelio [2018-06-01]
Post-Authorization Activity Table (PAAT) for Tresiba [2018-06-01]
Post-Authorization Activity Table (PAAT) for Vosevi [2018-06-01]
Post-Authorization Activity Table (PAAT) for Ocaliva [2018-06-01]
Regulatory Decision Summary for OPDIVO [2018-06-01]
Regulatory Decision Summary for BAVENCIO [2018-06-01]
Regulatory Decision Summary for XULTOPHY [2018-06-01]

May

Summary Basis of Decision (SBD) for ADDYI [2018-05-03]
Register of Innovative Drugs [2018-05-25]
Notice of Compliance (NOC) Data Extracts – May 25, 2018 [2018-05-25]
Product Monograph Brand Safety Updates – April 2018 [2018-05-30]
Qualifying Notice for Lynparza [2018-05-23]
Notice of Compliance (NOC) Data Extracts – May 18, 2018 [2018-05-18]
Notice: Revision of Guidance documents: Conduct and Analysis of Comparative Bioavailability Studies & Comparative Bioavailability Standards: Formulations used for Systemic Effects [2018-05-16]
Updated: Guidance Document: Patented Medicines (Notice of Compliance Regulations [2018-05-11]
Updated: Patent Register – Frequently Asked Questions [2018-05-11]
Updated Prescription Drug List (PDL) [2018-05-11]
Notice of Compliance (NOC) Data Extracts - May 11, 2018 [2018-05-11]
Regulatory Decision Summary for ADDYI [2018-05-10]
Regulatory Decision Summary for Lapelga [2018-05-10]
Regulatory Decision Summary for Norditropin NordiFlex [2018-05-10]
Submissions Under Review [2018-05-10]
Post-Authorization Activity Table (PAAT) for Adlyxine [2018-05-10]
Post-Authorization Activity Table (PAAT) for Viberzi [2018-05-09]
Post-Authorization Activity Table (PAAT) for Venclexta [2018-05-09]
Post-Authorization Activity Table (PAAT) for Cerdelga [2018-05-09]
Post-Authorization Activity Table (PAAT) for Lancora [2018-05-09]
Post-Authorization Activity Table (PAAT) for Rexulti [2018-05-09]
Post-Authorization Activity Table (PAAT) for Nitisinone Tablets [2018-05-08]
Post-Authorization Activity Table (PAAT) for Ninlaro [2018-05-07]
Consultation for Mandatory Requirements of using Electronic Common Technical Document (eCTD) Format when Submitting Master Files (MFs) [2018-05-07]
Notice of Compliance (NOC) Data Extracts – May 4, 2018 [2018-05-04]
Notice: Medical Device Single Audit Program (MDSAP) Reduction of Audit Times for Small-sized Enterprises – update [2018-05-04]
Warning Sticker and Opioid Patient Information Handout [2018-05-02]
Access to Generic Drugs in Canada [2018-05-02]
Regulatory Decision Summary for Jaydess [2018-05-02]
Regulatory Decision Summary for Simponi I.V. [2018-05-02]
Regulatory Decision Summary for Kisqali [2018-05-02]
Regulatory Decision Summary for Tecentriq [2018-05-02]
Regulatory Decision Summary for Taltz [2018-05-02]
Regulatory Decision Summary for Rituxan SC [2018-05-02]
Regulatory Decision Summary for Rekovelle [2018-05-02]
DPD Extracts [2018-05-01]

April

Summary Basis of Decision (SBD) for DATSCAN [2018-04-30]
Summary Basis of Decision (SBD) for FASENRA [2018-04-30]
Notice to Industry: ACSS - New Chemical Entities Work Sharing Trial Phase I [2018-04-30]
Notice of Compliance (NOC) Data Extracts [2018-04-27]
Updated Register of Certificates of Supplementary Protection and Applications [2018-04-27]
ICH S3A Questions and Answers: Note for Guidance on Toxicokinetics: The Assessment of Systemic Exposure – Focus on Microsampling [2018-04-26]
Register of Innovative Drugs [2018-04-26]
ICH M7(R1): Genotoxic Impurities - Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk [2018-04-26]
ICH E18: Genomic Sampling and Management of Genomic Data [2018-04-26]
What We Heard - Proposals for prescription drug transparency [2018-04-25]
Updated Register of Certificates of Supplementary Protection and Applications [2018-04-24]
Regulatory Decision Summary for GLYXAMBI [2018-04-20]
Register of Innovative Drugs [2018-04-20]
Regulatory Decision Summary for Dysport Therapeutic [2018-04-20]
Regulatory Decision Summary for Besponsa [2018-04-20]
Final Notice - Classification of Dental Plaque-disclosing Products as Drugs [2018-04-18]
Notice – Update on Health Canada's efforts to support innovative human therapeutic products to combat antimicrobial resistance (AMR) and consultation on a proposed Pathogens of Interest List [2018-04-17]
Regulatory Decision Summary for Prevymis [2018-04-17]
Regulatory Decision Summary for Blincyto [2018-04-17]
Regulatory Decision Summary for Orencia [2018-04-17]
Updated Register of Certificates of Supplementary Protection and Applications [2018-04-13]
Notice of Compliance (NOC) Data Extracts [2018-04-13]
Submissions Under Review [2018-04-13]
Product Monograph Brand Safety Updates – March 2018 [2018-04-10]
Regulatory Decision Summary for Sitavig [2018-04-10]
Regulatory Decision Summary for Auro-Cefixime [2018-04-10]
Regulatory Decision Summary for Xiidra [2018-04-10]
Regulatory Decision Summary for Cuvposa [2018-04-10]
Regulatory Decision Summary for Afluria Tetra [2018-04-10]
Scientific Advisory Panel on Isotretinoin Risk Management (SAP-IRM) - Membership and Biographies; Summary of Expertise, Experience and Affiliations and Interests; Record of Proceedings [2018-04-06]
Register of Innovative Drugs [2018-04-06]
Summary Basis of Decision (SBD) for Lonsurf [2018-04-06]
Updated Register of Certificates of Supplementary Protection and Applications [2018-04-06]
Notice of Compliance (NOC) Data Extracts – April 6, 2018 [2018-04-06]
ICH E11(R1) Addendum: Clinical Investigation of Medicinal Products in the Pediatric Population [2018-04-05]
Summary Basis of Decision (SBD) for Ozempic [2018-04-04]
ICH Q11: Questions and Answers: Selection and Justification of Starting Materials for the Manufacture of Drug Substances [2018-04-04]
ICH Q3C(R6): Impurities: Guidelines for Residual Solvants [2018-04-04]
DPD Extracts [2018-04-03]
Register of Innovative Drugs [2018-04-03]

March

Notice of Compliance (NOC) Data Extracts - March 29, 2018 [2018-03-29]
Notice: eCTD Pilot for Clinical Trial Regulatory Activities – Extension [2018-03-28]
Summary Basis of Decision (SBD) for Tremfya [2018-03-23]
Notice of Compliance (NOC) Data Extracts – March 23, 2018 [2018-03-23]
Register of Innovative Drugs [2018-03-23]
Product Monograph Brand Safety Updates - February 2018 [2018-03-23]
Regulatory Decision Summary for Ixiaro [2018-03-20]
Summary of Cancellation for Nivolumab (Opdivo) [2018-03-20]
Regulatory Decision Summary for Cutaquig [2018-03-20]
Regulatory Decision Summary for Fasenra [2018-03-20]
Regulatory Decision Summary for Zytiga [2018-03-20]
Updated Register of Certificates of Supplementary Protection and Applications [2018-03-20]
Submissions Under Review [2018-03-20]
New Drug Submission – Application Fee Form for Human and Disinfectant Drugs for submissions filed on or after April 1^st, 2018 [2018-03-16]
New Master File Applications Fee Form for Human Drugs for filing on or after April 1^st, 2018 [2018-03-16]
Notice of Compliance (NOC) Data Extracts – March 16, 2018 [2018-03-16]
Register of Innovative Drugs [2018-03-15]
Post-Authorization Activity Table (PAAT) for Brenzys [2018-03-13]
Post-Authorization Activity Table (PAAT) for Cinqair [2018-03-13]
Regulatory Decision Summary for Ocrevus [2018-03-13]
Regulatory Decision Summary for Prolia [2018-03-13]
Regulatory Decision Summary for Xiaflex [2018-03-13]
Summary Basis of Decision (SBD) for Velphoro [2018-03-12]
Notice - Prescription Drug List (PDL): Multiple Additions [2018-03-12]
Summary Basis of Decision (SBD) for Bavencio [2018-03-09]
Notice of Compliance (NOC) Data Extracts – March 9, 2018 [2018-03-09]
Updated Register of Certificates of Supplementary Protection and Applications [2018-03-09]
TPD Quarterly Drug Submission Performance report for Q3-2017-2018 [2018-03-02]
Notice of Compliance (NOC) Data Extracts – March 2, 2018 [2018-03-02]
Notice: Release of Draft (Step 2) ICH Guidance: Q12: Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management [2018-03-02]
DPD Extracts [2018-03-01]

Subscribe to our RSS Feeds